Physician profile
Thomas M Larkin
NPI 1043318587
$4,999.29
in general payments reported to CMS, 2019-2025
36 companies · $568 in 2025
The $568 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,050 · 2020: $687 · 2021: $551 · 2022: $883 · 2023: $587 · 2024: $673 · 2025: $568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,828.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,005.80 | 2019-2025 | Eterna, Proclaim, Octrode |
| Boston Scientific Corporation | $751.90 | 2019-2025 | Wavewriter Alpha Prime 16, Intracept |
| Nevro Corp. | $652.62 | 2020-2024 | Senza |
| Medtronic USA, INC. | $363.06 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $335.25 | 2020-2025 | Xtampza, Belbuca |
| Si-Bone, INC. | $234.78 | 2019-2022 | |
| Abbvie INC. | $203.38 | 2022-2025 | |
| Tersera Therapeutics LLC | $181.06 | 2019-2024 | Prialt |
| Amgen INC. | $131.31 | 2019 | |
| Medtronic, INC. | $127.51 | 2022-2025 | Kyphon Express II Kyphopak Tray, Intellis Adaptivestim, Inceptiv |
| Biotronik Nro, INC. | $93.22 | 2024-2025 | Prospera |
| Nuvasive, INC. | $84.01 | 2022 | |
| Lilly USA, LLC | $80.03 | 2019-2021 | |
| Allergan, INC. | $67.44 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $60.48 | 2019-2020 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Larkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.